苹果酸舒尼替尼治疗多次复发的晚期非小细胞肺癌疗效与安全性分析

BACKGROUND AND OBJECTIVE: Advanced non-small cell lung cancer (NSCLC) is a common malignancy that is incurable. No standard treatment exists for recurrent patients. This article analyzed the efficacy and safety of sunitinib (37.5 mg qd) on a continuous daily dosing (CDD) schedule in treating recurrent advanced NSCLC. METHODS: We retrospectively analyzed the short-term efficacy and toxicity of sunitinib CDD in treating 17 patients who had previously undergone multiple cycles of therapy for advanced NSCLC in our hospital from January 2011 to December 2012. Treatment-related survival was also analyzed. RESULTS: Among the 17 patients, the best overall response was partial response in 1 patient (5.9%), stable disease in 7 patients (41.2%), and progressive disease in 9 patients (52.9%). The overall response rate was 5.9%, and the disease control rate was 47.1%. The median progression-free survival was 4.4 months (95%CI: 4.05-7.46). The main grade 3/4 toxicity was hand-foot skin reaction. CONCLUSION: Sunitinib (37.5 mg QD) CDD enabled good objective response in advanced NSCLC patients who had previously received multiple cycles of treatment and was well tolerated.